Supernus Pharma (SUPN) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Supernus Pharma (SUPN) Tops Q3 EPS by 1c

Supernus Announces Third Quarter 2017 Financial Results

November 6, 2017 5:00 PM EST

Third quarter net product sales were $78.1 million, a 40% increase over 2016. Third quarter operating income was $22.3 million, a 13% increase over 2016.Initiated Phase III clinical trials for SPN-812.Initiated Oxtellar XR investigator-sponsored trial in bipolar disorder.Increased full year 2017 net product sales guidance range to $290 million to $295 million, from $280 million to $290 million, and operating income guidance range to $85 million to $90 million, from $82 million to $87 million.

ROCKVILLE, Md., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the... More